Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25769727 | 0.77 | — | — | |
| SCHEMBL13074193 | 0.77 | — | — | |
| SCHEMBL6845304 | 0.76 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL21011810 | 0.75 | — | — | |
| SCHEMBL21162057 | 0.75 | — | — | |
| Bromide SCHEMBL6844788 | 0.73 | KCNH2 (0.44) | KCNH2 | |
| SCHEMBL6843994 | 0.73 | KCNH2 (0.44) | KCNH2 | |
| SCHEMBL24753521 | 0.73 | — | — | |
| SCHEMBL23114283 | 0.73 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL24128100 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352353-B2 | Heterocyclic compound serving as FGFR4 inhibitor | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20200199120-A1 | HETEROCYCLIC COMPOUND SERVING AS FGFR4 INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| WO-2019160882-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352353-B2 | Heterocyclic compound serving as FGFR4 inhibitor | FGFR4, FGFR1, FGFR3 | KCNH2 4123/4885DRD2 2682/4885DRD4 2258/4885 |
| US-20200199120-A1 | HETEROCYCLIC COMPOUND SERVING AS FGFR4 INHIBITOR | FGFR4, FGFR1, FGFR3 | KCNH2 4123/4885DRD2 2682/4885DRD4 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.